Nothing said here yet.
to join the conversation.
The first dermatologist-developed skin longevity makeup brand debuts with its All-in-One Clinical Foundation, high-performance makeup powered by clinical-grade skincare TUCSON, Ariz., Oct.
Investors need to pay close attention to DERM stock based on the movements in the options market lately.
SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S.
Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
Emrosi prescriptions hit 14,000 in July as payer coverage expands and margins improve.
Journey Medical Corp (DERM) narrows net loss to $300K as Emrosi prescriptions hit all-time highs and payer access expands.
Moby summary of Journey Medical Corporation's Q2 2026 earnings call
Journey Medical (NASDAQ:DERM) reported higher second-quarter revenue and a sharply narrower net loss as sales of its rosacea treatment EMROSI continued to grow, supported by rising prescription volume, broader prescriber adoption and improving payer reimbursement.
The headline numbers for Journey Medical (DERM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Journey Medical (DERM) delivered earnings and revenue surprises of 0.00% and -1.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter Emrosi® revenues were $8.1 million for the second quarter of 2026 Strong revenue growth and disciplined cost management continue drive to profitability Company to hold conference call today at 4:30 p.m.